


REMARKS/ARGUMENTS

1. Information Disclosure Statements


Applicants thank the Examiner for considering the Information Disclosure Statement filed on March 11, 2009

2. Claim rejections under 35 USC §102

Claim 13 is rejected under 35 USC §102 as allegedly being anticipated by Kesarwani *et al.*, Tetrahedron Letters 43 (2002) 5579-81. Kesarwani *et al.* relates to solid-phase methods of synthesizing quinazolin-4(3H)-ones. The compounds described in Kesarwani *et al.* all have the formula.



wherein R₁ is required to be an anthranilic acid derivative (see Table 1). In particular, Kesarwani *et al.* discloses the following compound



In contrast, claim 13 has been amended to incorporate the features of claim 27, which the Examiner has indicated as being directed to allowable subject matter. Accordingly, the rejection is believed to be overcome and should be withdrawn.

3. Claim rejections under 35 USC §112, Second Paragraph

With respect to the term “thio,” Applicants respectfully submit that those skilled in the art would readily understand that the term, when used as part of a Markush group to describe optional

substituents, includes -SR, -S- and =S containing groups. However, solely for the purpose of advancing prosecution of the present application claims 13 and 31 are being amended to delete the reference to "thio" group "

4. Objections to the claims

Claims 27 and 29 are objected to as being dependent upon a rejected base claim. Claim 27 is being cancelled. Claim 29 is being amended to be in independent form

5. Miscellaneous Claim Amendments

Claims 13 and 29 are also being amended to provide specific optional substituents for substituent K, similar to those provided in claim 28

CONCLUSION

Applicants earnestly believe that they are entitled to a letters patent, and respectfully solicit the Examiner to expedite prosecution of this patent application to issuance. Should the Examiner have any questions, the Examiner is encouraged to telephone the undersigned.

If there are any additional fees due in connection with the filing of this amendment, the Commissioner is authorized to charge any such additional fees to Takeda San Diego's Deposit Account No **50-2256**. If any extensions or fees are not accounted for, such extension is requested and the associated fee should be charged to said deposit account.

Respectfully submitted,

TAKEDA SAN DIEGO, INC.

Dated. September 22, 2009

Customer No **32793**
Takeda San Diego, Inc.
10410 Science Center Drive
San Diego, CA 92121
Telephone: (858) 622-8528
Facsimile: (858) 550-0992

By: 
Mitchell R. Brustein
Reg. No 38,394